Results 31 to 40 of about 3,302 (197)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

Annals of the Rheumatic Diseases, 2021
Objective Janus kinase inhibitors (JAKinibs) are efficacious in rheumatoid arthritis (RA) with variable reported rates of adverse events, potentially related to differential JAK family member selectivity.
Paqui G Través, B. Murray, F. Campigotto, R. Galien, A. Meng, J. D. Di Paolo   +5 more
semanticscholar   +1 more source

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial [PDF]

Intestinal Research, 2023
Background/Aims The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial.
Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Katsuyoshi Matsuoka, Masayuki Saruta, Taku Kobayashi, Brian G Feagan, Chantal Tasset, Robin Besuyen, Chohee Yun, Gerald Crans, Jie Zhang, Akira Kondo, Mamoru Watanabe   +15 more
doaj   +1 more source

Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate

Rheumatology and Therapy, 2023
Introduction Our aim was to evaluate protein biomarker changes related to the administration of filgotinib, a Janus kinase (JAK) 1 preferential inhibitor, in patients with moderately to severely active rheumatoid arthritis (RA) with inadequate response ...
Yoshiya Tanaka, Peter C. Taylor, Emon Elboudwarej, Angie Hertz, Xiaorong Shao, Vladislav A. Malkov, Hironori Matsushima, Kahaku Emoto, Bryan Downie, Tsutomu Takeuchi   +9 more
doaj   +1 more source

Filgotinib: A Clinical Pharmacology Review

Clinical Pharmacokinetics, 2022
Filgotinib (GS-6034, formerly GLPG0634; Jyseleca®) is an oral, preferential Janus kinase (JAK)-1 inhibitor. Preferential inhibition of JAK1 modulates a subset of proinflammatory cytokines within the JAK-signal transducer and activator of transcription pathway, which differ from those inhibited by JAK2 or JAK3.
Florence Namour, Kacey Anderson, Cara Nelson, Chantal Tasset   +3 more
openaire   +2 more sources

Validated DBS method for filgotinib quantitation in rat dried blood spots and its application to a pharmacokinetic study in rats

ADMET and DMPK, 2020
Filgotinib is a selective JAK1 (Janus kinase) inhibitor, showed efficacy in patients suffering from moderate-to-severe rheumatoid arthritis. In this paper, we present the data on the development and validation of a sensitive, selective and high ...
Abhishek Dixit, Vinay Kiran, Bhavesh Babulal Gabani, Ramesh Mullangi   +3 more
doaj   +1 more source

Filgotinib in Rheumatoid Arthritis: A Profile of Its Use [PDF]

Clinical Drug Investigation, 2021
Filgotinib (Jyseleca®), an oral Janus kinase (JAK) inhibitor, is approved as monotherapy or in combination with methotrexate to treat moderate to severe active rheumatoid arthritis (RA) in adults who have an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).
Esther S. Kim, Susan J. Keam
openaire   +2 more sources

Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3

RMD Open, 2021
Objective This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with multiple poor prognostic factors (PPFs).Methods This was a ...
René Westhovens, Thijs Hendrikx, Beatrix Bartok, Cécile Gaujoux-Viala, Giovanni Adami, Zhaoyu Yin, Ying Guo, Osvaldo Daniel Messina, Alan Matsumoto   +8 more
doaj   +1 more source

Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis

Frontiers in Bioscience-Landmark, 2023
Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease that causes progressive joint damage. The Janus kinase (JAK) inhibitors (JAK-I) represent a new therapeutic option for RA patients, blocking the intracellular JAK-STAT pathway. Today,
Maurizio Benucci, Francesca Li Gobbi, Paola Fusi, Arianna Damiani, Edda Russo, Serena Guiducci, Mariangela Manfredi, Valentina Grossi, Maria Infantino, Amedeo Amedei   +9 more
doaj   +1 more source

Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: analysis of the phase 2b/3 SELECTION study [PDF]

Intestinal Research
Background/Aims Obtaining and maintaining corticosteroid-free remission are important goals of treatment for ulcerative colitis (UC). Characteristics associated with achieving corticosteroid-free remission were assessed in filgotinib-treated patients in ...
Taku Kobayashi, Axel Dignass, Xavier Roblin, Yoshie Takatori, Toshihiko Kaise, Alessandra Oortwijn, Corinne Jamoul, Toshifumi Hibi   +7 more
doaj   +1 more source

Filgotinib in Crohn’s Disease: JAK Is Back [PDF]

Gastroenterology, 2017
n ...
Danese, Silvio, Fiorino, Gionata, Peyrin-Biroulet, Laurent   +2 more
openaire   +3 more sources